ArticleNature genetics2024
Five latent factors underlie response to immunotherapy.
Article in Nature genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Smart drug delivery systems for immunotherapeutic agents: focus on biological/biogenic platform-based intelligent delivery in cancer immunotherapy.Drug delivery and translational research · 2026Review
- Systematic identification of genomic nonresponse biomarkers to cancer therapies.ESMO real world data and digital oncology · 2026Article
- Exploring plasma cell-free RNA biomarkers for predicting immune checkpoint inhibitor efficacy in gastric cancer: a translational sub-study of the KSCC VOYAGER phase II trial.International journal of clinical oncology · 2026Article
- A network-based deep learning model integrating subclonal architecture for therapy response prediction in cancer.Cell reports methods · 2026Article
- Understanding immune checkpoint inhibitor efficacy through spatial decoding of the lung cancer tumor immune microenvironment.The Journal of clinical investigation · 2026Article
- Tumors hijack immune-privileging regulons via distinct cell types to confer T cell desertion and immunotherapy resistance across various cancers.Nature communications · 2026Article
- Article
- Discovery of predictive biomarkers for cancer therapy through computational approaches.Nature reviews. Clinical oncology · 2026Review
- Next-Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy.Journal of immunology research · 2026Review
- TGF-β builds a dual immune barrier in colorectal cancer by impairing T cell recruitment and instructing immunosuppressive SPP1Nature genetics · 2025Article
- Two-pronged immunosuppression by TGFβ supports colorectal cancer metastasis.Nature genetics · 2025Article
- Overlapping Extremes: An Analysis of Avelumab Maintenance and Pembrolizumab in Advanced Urothelial Carcinoma.Oncology and therapy · 2025Article
- 33 Unresolved Questions in Nanoscience and Nanotechnology.ACS nano · 2025Article
- Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade-Treated Advanced Melanoma: A Retrospective Analysis.Cancer research communications · 2025Article
- RNF213 governs divergent tumor-immune dynamics across human cancers: a prognostic biomarker for immunotherapy stratification.Discover oncology · 2025Article
- SITC perspective: leveraging patient enrichment biomarkers to accelerate early phase IO drug development.Journal for immunotherapy of cancer · 2025Article
- Genetic immune escape in cancer: timing and implications for treatment.Trends in cancer · 2025Review
- Polysaccharides from Sea Cucumber (Foods (Basel, Switzerland) · 2025Article
- Application of immunotherapy in advanced non-small cell lung cancer with hypertension: a multicenter retrospective analysis.Frontiers in oncology · 2025Article
- Reprogramming cancer immunity with next-generation combination therapies.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Only a subset of patients treated with immune checkpoint inhibitors (CPIs) respond to the treatment, and distinguishing responders from non-responders is a major challenge. Many proposed biomarkers of CPI response and survival probably represent alternative measurements of the same aspects of the tumor, its microenvironment or the host. Thus, we currently ignore how many truly independent biomarkers there are. With an unbiased analysis of genomics, transcriptomics and clinical data of a cohort of patients with metastatic tumors (n = 479), we discovered five orthogonal latent factors: tumor mutation burden, T cell effective infiltration, transforming growth factor-beta activity in the microenvironment, prior treatment and tumor proliferative potential. Their association with CPI response and survival was observed across all tumor types and validated across six independent cohorts (n = 1,491). These five latent factors constitute a frame of reference to organize current and future knowledge on biomarkers of CPI response and survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.